| ADHD Therapeutics Market to 2018 |
 |
|
|
|
New
Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment
|
|
The impending publication of
the fifth edition of the American Psychiatric Association's (APA) Diagnostic and Statistical Manual
of Mental Disorders (DSM-V) may affect diagnosis rates of
conditions such as Attention-Deficit/Hyperactivity Disorder (ADHD), both in
the US and worldwide.
European countries are
increasingly adopting the US diagnostic criteria (DSM-IV), resulting in more
and more diagnoses of ADHD. This may eventually result in a rise in ADHD
diagnoses even further afield.
|
 |
|
|
Although Europe
trails behind the US in terms of market revenue, ADHD therapeutics markets
are expected to show strong growth, with Spain
predicted to witness a Compound Annual Growth Rate (CAGR) of 8% over
2012-2018, beating the US CAGR of 6% during the same future period. European
markets have not yet neared the saturation point that ADHD therapeutics are
facing in the US, and there is an optimistic view for ambitious growth in
this region. The ADHD therapeutics market across France, Germany, Italy,
Spain and the UK is predicted to reach approximately $182m in 2018.
GBI Research's report "ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates
of Treatment" provides insights into the up-and-coming
trends of the ADHD market in seven major markets: the US, the top five
European countries (France, Germany, Italy, Spain and the UK) and Japan. The
report includes market forecasts to 2019, detailed pipeline analysis,
in-depth profiling of major products and details of recent industry deals.
|
||
|
No comments:
Post a Comment